{
    "clinical_study": {
        "@rank": "141341", 
        "acronym": "PETRA", 
        "arm_group": {
            "arm_group_label": "Advanced NSCLC patients undergoing first-line chemotherapy", 
            "arm_group_type": "Other", 
            "description": "single cohort"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to test whether an early metabolic response, measured by PET/CT\n      scan after the first cycle of chemotherapy, is able to predict which patients with advanced\n      NSCLC have a better prognosis."
        }, 
        "brief_title": "PET/CT Scan as a Tool to Rationalize the Treatment of of Advanced NSCLC Patients Undergoing First Chemotherapy", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Non-small Cell Lung Cancer Metastatic", 
            "Non-small Cell Lung Cancer Stage IIIB"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms", 
                "Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of cytologically or histologically confirmed non-small cell lung cancer.\n\n          -  Metastatic (stage IV, both M1A or M1B) or locally advanced (stage IIIB, with\n             metastasis to supraclavicular nodes) according to TNM VII edition.\n\n          -  Both patients at first diagnosis or those with disease recurrence after initial\n             surgery are eligible.\n\n          -  At least one target or non-target lesion according to RECIST revised version 1.1.\n\n          -  Age > or = 18 years .\n\n          -  ECOG PS 0-2.\n\n          -  Life expectancy > 3 months.\n\n          -  Signed informed consent.\n\n        Exclusion Criteria:\n\n          -  Uncontrolled diabetes (glucose > 200 mg/dl\n\n          -  EGFR mutation, for those patients who have had testing done.  (EGFR test is not\n             required for participation in the study, but may be conducted as part of normal\n             clinical practice, and patients with EGFR mutation would not be candidate for\n             first-line chemotherapy.)\n\n          -  Any other malignancies within 5 years (except for adequately treated carcinoma in\n             situ of the cervix or basal or squamous cell skin cancer or surgically resected\n             prostate cancer with normal PSA).\n\n          -  Pregnant or lactating females.\n\n          -  Previous medical therapy for metastatic disease (prior surgery, radiation therapy are\n             permitted, as well as adjuvant medical therapy completed at least 6 months prior to\n             study entry).\n\n          -  Any poorly controlled  illness (including active infections, significant hepatic,\n             renal, metabolic or cardiac disease, myocardial infarction within previous 12 months)\n             that may, according to physician's judgement,  interfere with the patient's ability\n             to  undergo chemotherapy and/or the examinations within the study protocol\n\n          -  Inability to provide informed consent."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "220", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02035683", 
            "org_study_id": "PETRA"
        }, 
        "intervention": {
            "arm_group_label": "Advanced NSCLC patients undergoing first-line chemotherapy", 
            "description": "PET/CT scan at baseline and 3 weeks after first cycle chemotherapy", 
            "intervention_name": "PET/CT", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "metabolic response", 
            "chemotherapy"
        ], 
        "lastchanged_date": "February 20, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Napoli", 
                    "country": "Italy"
                }, 
                "name": "Istituto Nazionale dei Tumori"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "1", 
        "official_title": "Study of the Role of Metabolic Response Measured by PET/CT Scan After 1 Cycle of Chemotherapy in Patients With Advanced Non Small Cell Lung Cancer (NSCLC)", 
        "overall_contact": {
            "email": "francesco.perrone@usc-intnapoli.net", 
            "last_name": "Francesco Perrone, M.D., Ph.D.", 
            "phone": "+39 081 5903571"
        }, 
        "overall_contact_backup": {
            "email": "marilina.piccirillo@usc-intnapoli.net", 
            "last_name": "Maria Carmela Piccirillo, M.D.", 
            "phone": "+39 081 5903383"
        }, 
        "overall_official": [
            {
                "affiliation": "National Cancer Institute, Naples", 
                "last_name": "Secondo Lastoria, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "National Cancer Institute Naples, Italy;  Director Clinical Trials Unit", 
                "last_name": "Francesco Perrone, M.D., Ph.D", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Second University of Naples, Italy; Chair of Medical Statistics", 
                "last_name": "Ciro Gallo, M.D., Ph.D", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "National Cancer Institute, Naples", 
                "last_name": "Massimo Di Maio, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "National Cancer Institute, Naples", 
                "last_name": "Alessandro Morabito, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "National Cancer Institute, Naples", 
                "last_name": "Gaetano Rocco, M.D.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To validate as prognostic factor, in terms of overall survival,early metabolic response, defined as a reduction of more than 50% of the highest value of SUVmax recorded at PET/CT scan after one cycle of chemotherapy, compared to the highest value of SUVmax recorded baseline examination", 
            "measure": "change from baseline in highest value SUVmax (maximum standardized uptake values in PET/CT scan)", 
            "safety_issue": "No", 
            "time_frame": "one year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02035683"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "to describe and validate early metabolic response as a prognostic factor (in terms of overall survival), using  the sum of the SUVmax (SUVmaxsum) , the highest value of TLG (TLGmax), the sum of TLG ( TLGmaxsum).", 
                "measure": "Change from baseline in SUVmaxsum, TLGmax and TLGmaxsum", 
                "safety_issue": "No", 
                "time_frame": "one year"
            }, 
            {
                "description": "prognostic role of early metabolic response (defined according the above reported 4 parameters) in terms of progression free survival after a first line chemotherapy", 
                "measure": "correlation among SUVmax, SUVmaxsum, TLGmax, TLGsum with progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "one year"
            }, 
            {
                "description": "To describe the association between early metabolic response (defined according the above reported 4 parameters) and objective response according RECIST criteria, measured after 3 cycles of chemotherapy", 
                "measure": "correlation among SUVmax, SUVmaxsum, TLGmax, TLGsum with objective response", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "overall survival", 
                "safety_issue": "No", 
                "time_frame": "one year"
            }, 
            {
                "measure": "progression free survival", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "objective response", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }
        ], 
        "source": "National Cancer Institute, Naples", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute, Naples", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}